Improving treatments for Fuchs endothelial corneal dystrophy using Rho-associated kinase inhibitors
Optimizing Rho-associated kinase inhibitors for use in treating Fuchs endothelial corneal dystrophy
This study is looking at how two medications, netarsudil and ripasudil, can help slow down the vision loss caused by Fuchs endothelial corneal dystrophy, with the hope of finding a better treatment that might reduce the need for corneal transplants.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-10684764 on NIH RePORTER |
What this research studies
This research focuses on Fuchs endothelial corneal dystrophy (FECD), a condition that leads to vision loss and often requires corneal transplants. The study aims to evaluate the effectiveness of two Rho-associated kinase inhibitors, netarsudil and ripasudil, in preventing the progression of FECD. By comparing these treatments, the researchers hope to identify a more effective option that could reduce the need for surgery. The approach includes assessing how these inhibitors affect corneal endothelial cells and their ability to promote healing.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals over 40 years old who have been diagnosed with Fuchs endothelial corneal dystrophy.
Not a fit: Patients with advanced FECD who have already undergone corneal transplantation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option to prevent vision loss in patients with Fuchs endothelial corneal dystrophy.
How similar studies have performed: Previous studies have shown promise with Rho-associated kinase inhibitors in related applications, but this specific comparison of netarsudil and ripasudil is novel.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Greiner, Mark Aaron — University of Iowa
- Study coordinator: Greiner, Mark Aaron
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.